- Seven New Senior Vice President and Vice President Positions Filled -
GAITHERSBURG, Md., Dec. 6 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) announced today that it continues to build strength and depth
in its management ranks through promotions and new hires. Recognizing their
leadership and outstanding performance, MedImmune has promoted William C.
Bertrand, Jr., J.D. to senior vice president, general counsel, secretary and
corporate compliance officer; Pamela J. Lupien to senior vice president, human
resources; Genevieve Losonsky, M.D. to vice president, clinical development,
infectious disease; and Robert Walker, M.D. to vice president, clinical
development, inflammatory disease. In addition, MedImmune has recruited
Anthony Luttrell as vice president, quality; Frank J. Malinoski, M.D., Ph.D.
as vice president, medical affairs, infectious disease; and John J. Whalen,
M.D. as vice president, clinical development operations.
"Bill Bertrand, Pam Lupien, Genny Losonsky and Bob Walker have led by
example and delivered results. They exemplify our core values of high
integrity, entrepreneurial spirit, teamwork and strong work ethic," said David
M. Mott, chief executive officer and president. "We are grateful for the
opportunity to recognize their contributions to our success through these
promotions and look forward to their leadership in their new roles at
Mott added: "As MedImmune continues to grow, it is critical that we
selectively complement the growth of our existing leadership team with the
addition of outside talent. Our ability to attract extraordinarily talented
executives to the team has never been greater, as exemplified by the addition
of Tony Luttrell, Frank Malinoski and Jack Whalen. We welcome them and look
forward to their contributions to MedImmune's continued growth."
William C. Bertrand, Jr., J.D. has been promoted to senior vice president,
general counsel, secretary and corporate compliance officer. Mr. Bertrand
joined MedImmune in 2001, and held positions of increasing responsibility
prior to his promotion. Under his leadership, MedImmune's legal affairs
department has grown significantly and has steadily increased its ability to
lead and manage a broad range of corporate legal matters, intellectual
property issues and litigation. Mr. Bertrand and his team are sought out as
strategic partners by our internal business leaders. Prior to joining
MedImmune, he served in various legal positions at Pharmacia Corporation,
including litigation counsel, senior corporate counsel and associate general
counsel. Mr. Bertrand spent the earlier part of his legal career as an
associate general counsel for a life insurance company, and a partner at
Dickinson, Wright, Moon, Van Dusen & Freeman. Mr. Bertrand holds a bachelor of
science degree in biology from Wayne State University and a juris doctorate
(cum laude) from University of Wisconsin - Madison. Mr. Bertrand was recently
named "Top Washington Lawyer - General Counsel" by the Washington Business
Pamela J. Lupien has been promoted to senior vice president, human
resources. Ms. Lupien joined MedImmune as vice president of human resources in
April 2002. She spearheaded the recent growth in MedImmune's human resources
organization, which includes the environmental health and safety function in
six locations and three countries. Her organization has recently completed the
implementation of a restructured compensation model, new leadership
development program and a corporate capabilities program, which aims to
systematically enable the development of MedImmune's employees, and accelerate
the growth of leadership talent within the organization. Prior to joining
MedImmune, Ms. Lupien worked for the Orbital Sciences Corporation as senior
vice president, human resources, from 2000 until 2002. Previously, she held a
variety of increasingly responsible positions at James Martin & Company,
Betzdearborn, Inc., Freuhauf Trailer Corporation, and IBM Corporation. Ms.
Lupien has a bachelor's degree in social sciences from the University of South
Florida and a master's degree in business administration from Jacksonville
Genevieve Losonsky, M.D. has been promoted to vice president, clinical
development, infectious disease. Since joining the company in 2002, Dr.
Losonsky has served as project director for several clinical programs
involving MedImmune's respiratory syncytial virus prevention franchise,
including the Numax(TM) (motavizumab) program. Prior to joining MedImmune, Dr.
Losonsky held faculty positions at the University of Maryland School of
Medicine, where she was an associate professor in the Department of Pediatrics
and Medicine, and at the Center for Vaccine Development, where she served as
chief of the Applied Immunology Laboratory. Dr. Losonsky has published
approximately 110 journal articles and 50 abstracts related to infectious
diseases and vaccines, in addition to multiple book chapters and symposia. She
received a bachelor's degree in biology and psychology from New York
University and a medical degree from the State University of New York at
Buffalo. Dr. Losonsky completed her residency in pediatrics at Yale New Haven
Hospital, Yale University Department of Pediatrics, and also completed a
research and clinical fellowship in infectious diseases at Buffalo Children's
Hospital and a National Institutes of Health (NIH) fellowship in infectious
diseases at Johns Hopkins University. She currently is a peer reviewer for the
pediatric journals Pediatric Infectious Diseases, Infection and Immunity, and
Pediatrics, and a member of the Society for Pediatric Research and the
Infectious Disease Society of America.
Robert Walker, M.D., has been promoted to vice president, clinical
development, inflammatory disease. In this position, he will oversee
MedImmune's clinical trials of new product candidates aimed at preventing or
treating various autoimmune and pulmonary diseases. Dr. Walker is currently
the project director for the intranasal influenza vaccine program at MedImmune
and will continue to be the senior project lead for that program. Prior to
joining the biotechnology industry, Dr. Walker was a senior investigator in
the Laboratory of Immunoregulation at the National Institute of Allergy and
Infectious Diseases and a senior attending physician in Critical Care Medicine
at the NIH Clinical Center. During this time, Dr. Walker did research in human
immunodeficiency virus (HIV) and immunology. Dr. Walker holds a bachelor of
arts degree from Vassar College and a medical degree from the University of
Maryland School of Medicine. He completed an internal medicine residency at
George Washington University and a fellowship in pulmonary and critical care
medicine at the University of Pennsylvania.
New Executives at MedImmune
Anthony Luttrell has been appointed MedImmune's vice president, quality.
In this position, Mr. Luttrell is responsible for the strategic direction of
MedImmune's quality organization and oversees the company's quality assurance,
quality control, compliance, validation and clinical quality departments. Mr.
Luttrell began consulting with MedImmune in 2000. Previously, he held quality-
related management positions at Parke-Davis/Warner-Lambert, Baxter Healthcare,
Kendall McGaw Pharmaceuticals, Solvay Animal Health, Inc. and BioPort
Corporation. Mr. Luttrell brings to MedImmune more than 25 years of experience
in the pharmaceutical, biopharmaceutical and medical device industries. He
holds a bachelor's degree in biology from Spring Arbor College in Michigan, an
MBA from Oakland University in Michigan, and a certification from the
Minnesota Executive Development Program of the Carlson School of Business at
the University of Minnesota.
Frank J. Malinoski, M.D., Ph.D. joins MedImmune as vice president, medical
affairs, infectious disease, where he will oversee medical programs relating
to marketed infectious disease products, including clinical trials and medical
information. Prior to joining MedImmune, Dr. Malinoski served as president of
his consulting practice, TD Consultancy. He also worked for pharmaceutical and
biotechnology companies such as Oxxon Therapeutics, Inc. and Wyeth, where he
held positions as chief medical officer and executive vice president,
development, and vice president, global business development, respectively.
Previously, Dr. Malinoski served as a private practice physician in Frederick,
Maryland. Dr. Malinoski received a bachelor's degree in biology from Colby
College in Waterville, Maine, a Ph.D. in microbiology from Rutgers University
and a medical degree from Albany Medical College.
John J. Whalen, M.D., has joined MedImmune as vice president, clinical
development operations. In this role, Dr. Whalen provides leadership,
strategic planning and effective management to all functional areas within
clinical operations, data management, biostatistics and programming groups.
Prior to joining MedImmune, Dr. Whalen worked for the clinical contract
research organization, Scirex Corporation, as general manager, clinical
development services. Dr. Whalen has more than 25 years of experience in the
pharmaceutical, contract research and biotechnology industries. Prior to
Scirex, he held positions in clinical research and operations at Merck, Sharp
and Dohme Research Laboratories, G.H. Besselaar Associates (now Covance),
Alpha Therapeutic Corporation and Transcend Therapeutics, Inc. He holds a
bachelor of science degree in physics from Rensselaer Polytechnic Institute, a
medical degree from the University of Virginia Medical School, and completed
an internal medicine residency training at Memorial Sloan Kettering Cancer
Center and North Shore University Hospital.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With more than 2,000 employees worldwide,
MedImmune is headquartered in Maryland. For more information, visit the
company's website at http://www.medimmune.com.
SOURCE MedImmune, Inc.
Clarencia Stephen, +1-301-398-4073
Peter Vozzo, +1-301-398-4358
all of MedImmune, Inc.